

Q-linea participates in first public tender in Belgium

Q-linea AB (publ) (OMX: QLINEA) today announces that the company has participated in a public tender in Belgium with the ASTar® Instrument and Consumables through its Distribution Partner Biomedical Diagnostics.

The tender at Cliniques Universitaires St. Luc is a result of a comparative study with 3 different rapid AST systems enrolling 200 patients which provided evidence of robust performance and a significantly shorter time to optimal therapy for patients with bloodstream infections.

"We are excited to participate in this tender at Cliniques Universitaires St. Luc through our partner Biomedical Diagnostics. This is the first project we have seen in Belgium with a specific focus on rapid AST solutions directly from positive blood culture bottles and the first opportunity to establish ASTar as a reference system in the Region" said Franco Pellegrini, Sales Director Southern Europe at Q-linea.

For more information, please contact:

Stuart Gander, President & CEO, Q-linea Stuart.Gander@qlinea.com +1 857 409 7463

Christer Samuelsson, CFO /IR, Q-linea AB Christer.Samuelsson@qlinea.com +46 (0) 70-600 15 20

About Q-linea

Q-linea's rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.

Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.

ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com

Attachments

Q-linea participates in first public tender in Belgium